We studied the immune functions of two patients with angioimmunoblastic lymphadenopathy (AILD) 
Introduction
Angioimmunoblastic lymphadenopathy (AILD)' is a disorder that has been described in the last 30 yr (1), but which has malities, the adenopathy consists of polyclonally activated immunoblasts, often B cells, without obvious malignancy. Nevertheless, the typical patient has a life expectancy of -I yr. Most patients with AILD die of infection. A minority of patients go on to develop a frank lymphoreticular malignancy; the potential to develop such a malignancy may possibly be predicted on the basis of hyperdiploidy of lymphoid cells early in the course of the illness (6) . Although the clinical features have led to the belief that AILD is a single illness, differences have been stressed in some reports (7) , and it is possible that AILD represents a syndrome with more than one clinicopathologic syndrome and/or more than one etiology.
Although the clinical and pathologic features of patients with AILD are becoming better understood, there is considerable confusion regarding the cellular abnormalities that underlie this disorder (7) (8) (9) (10) (11) (12) (13) . Most patients have an abnormal composition of their peripheral blood leukocytes. It has been suggested that suppressor T cell functions may be deficient in AILD, thereby leading to B cell hyperactivity (9) . Autonomous B cell hyperactivity has been proposed by other investigators as the major problem in the disorder (7) . However, patients with AILD may vary over time so that cellular functions may be different at different times; moreover, the exact mechanisms of B cell hyperactivity are not well defined by the previous studies. Because anti-erythrocyte autoantibodies are found in many patients (2) , and there is an association with other autoimmune syndromes (14-16), understanding the immune basis of AILD might shed light upon other diseases as well. For these reasons, as well as the rapidly progressive nature of the disorder, we undertook a study of the cellular basis of disease in two patients with AILD. We were aided in our human studies by observations in two mouse strains, MRLlpr/lpr and C3H-gld/gld. These two strains also develop massive lymphadenopathy, hypergammaglobulinemia, and autoantibodies (17) (18) (19) (20) . Their T cells produce factors that can activate B cells and drive them to proliferate and become immunoglobulin secreting cells (17) . Therefore, our studies attempted to determine whether AILD B cells were spontaneously hyperactive or whether an excess of helper T cell function might underlie the syndrome. The studies suggest that AILD T cells activate B cells and drive them to proliferate and to produce immunoglobulin. We also conducted experiments to explain the paradoxical impaired responsiveness to in vitro stimulation with pokeweed mitogen by B cells which are active in vivo (21) (22) (23) (24) (25) .
Methods
Patients and source of lymphocytes and plasma. Patients with AILD and systemic lupus erythematosus (SLE) were hospitalized at the Clinical Center, National Institutes of Health, Bethesda, Maryland; the patients agreed in writing to being studied according to an approved informed consent form. The patients with AILD had classic lymph node histology and clinical symptomatology (2) (3) (4) (5) . They were studied early in the course of their illness. Lymphocytes and plasma from the patients with AILD used in in vitro studies were obtained before any treatment. Plasma of patients with AILD used in this study had been fresh frozen and had not been previously thawed. All plasma were centrifuged at 13,000g for 15 min at 40C to remove aggregated materials before use.
Isolation of T cells, B cells, and monocytes. Peripheral blood mononuclear cells (MNC) were isolated by Ficoll-Hypaque gradient centrifugation. T cells, and non-T cells were separated from MNC by rosetting with neuraminidase-treated sheep erythrocytes (26, 27 Interleukin-1 (IL-I) assay. The IL-i assay was performed as described (28) . Briefly, a single cell suspension of thymocytes (1.5 X 107/ml) from C3H/HeJ mice was prepared and suspended in RPMI 1640 with 5% fetal calf serum, 2.5 X l0on M 2-mercaptoethanol 2 mM L-glutamine, and antibiotics. Thymocytes were cultured for 72 h at 1. Interleukin-2 (IL-2) assay. Plasma or supernates from NMC, T cells, or a T cell line were tested for their ability to maintain the growth of the IL-2-dependent HT-2 T cell clone (29 (30) , and characterized in our previous paper (31) . Briefly, this antibody recognizes an Ia-like determinant on non-T cells (a 28,000/32,000-mol wt heterodimer) and interferes with B cell activation more effectively than conventional anti-HLA-DR and anti-HLA-DS/DC reagents.
Results
Studies of AILD T cells. Because AILD is characterized by marked numbers of immunoblasts and production of large amounts of antibody, we wished to study whether the T cells might be important in the induction of B cell activation, proliferation, and/or differentiation. Either the AILD T cells are important in such induction or the AILD B cells are spontaneously hyperactive or non-T cell stimuli (e.g., exogenous agents) might be responsible for the B cell hyperactivity.
We obtained fresh MNC from two patients with AILD and studied their ability to induce B cell proliferation and differentiation. We found that spontaneous culture supernate of T cells obtained from each patient induced substantial proliferation of B cells (B cell activation activity) as well as proliferation in a standard costimulatory assay (BCGF activity) ( Table I) . Neither of these properties of AILD T cells was found among 10 normal controls studied at the same time and in an identical manner. In addition, there was no detectable IL-I or IL-2 activity in the AILD T cell supernates. The whole mononuclear cell supernate (MNC-CS) did not have B cell activating or BCGF activities. In that this is the same population from which the T cells were obtained for the T cell supernate, we presume that either other cells are capable of inhibiting production of the factor(s), or, more likely, that they can absorb out or conceivably destroy the factors. In Table I we have listed the results of the assay for B cell activating factor Table I Patients with AILD are often quite ill and require vigorous therapy. We did not want to depend on fresh T cells from our patients, whom we knew would receive therapies that could alter their cellular functions. To study systematically the properties of the AILD T cells and to obtain enough supernate to do many studies, we tried to establish a T cell line from both patients. We were successful with one. The T cell line was 100% OKT 3+ OKT 4+, and also expressed activated cell markers: OKT 9 (transferin receptor) 27%, OKT 10 (activated T cell marker) 39%, Leu-10 (HLA-DS/DC/MB) 10%, HLA-DR 28%, and Tac (IL-2 receptor) 29%.
Ability of the AILD T cell line to induce proliferation of autologous and allogeneic B cells. The AILD T cell line was compared with fresh normal T cells and T cell lines from two patients with SLE for the ability to induce B cells to proliferate. All T cells were irradiated before culture so that their contribution to the proliferation would be eliminated (this was confirmed; data not shown). We found that the fresh normal T cells failed to induce dramatic proliferation of B cells. This was true whether allogeneic or autologous B cells were used (Table II) . Moreover, the AILD B cells did not proliferate spontaneously (data not shown), nor were they induced to proliferate by fresh normal T cells (Table II) . In contrast, the AILD T cell line induced both allogeneic and autologous B cells to proliferate dramatically (Table II) . The SLE T cell lines also induced significant proliferation; however, this was not as great as that induced by the AILD T cell lines.
Ability ofthe AILD T cell line to induce B cells to produce immunoglobulin. We next asked whether, in addition to inducing proliferation of B cells, the AILD T cell line could induce Ig secretion. The data in Table III show that the AILD T cell line can, in fact, induce Ig production by unstimulated (Table IV) . The greatest degree of proliferation was induced by the supernate of the AILD T cell line (-20-fold) ( Table IV) .
The addition of anti-A to the cultures containing B cells plus the AILD T cell line supernate led to an additional increase of -1.5-2-fold in proliferation (Table IV) (Table  VI) . Whereas the fresh T cells caused only a twofold increase or less, the AILD T cell line caused a 19-30-fold increase. However, the combination of fresh T cells plus PWM caused as good proliferation as did the AILD T cells. Thus, the AILD T cells provided an extremely strong proliferative signal. When PWM and the AILD T cell line were combined, the result was not a further increase, but rather, a decrease of 60% (Table  VI) . We then asked whether this was a result of suprastimulation. No evidence for this could be found in that further addition of anti-a and/or PHA-CS to the culture of the AILD T cell line plus B cells (without PWM) led to even more proliferation (data not shown). Thus, there appeared to be something special about the combination of stimulation with PWM plus the AILD T cell line which led to suppression of B cell proliferation relative to that observed with the AILD T cell line alone. We pursued this observation in the hope that it might shed some light upon the previously reported defect in the SLE MNC response to PWM as well as on the AILD T cells.
This suppression in association with PWM was further studied in a mixing experiment in which both the AILD T cell line and fresh T cells were added to cultures of B cells, and total Ig was assayed (Fig. 1) . The fresh T cells plus PWM led to Ig production as did the AILD T cell line without PWM. However, the AILD T cell line plus PWM, with or without fresh T cells, led to marked suppression. This result suggested that PWM might be inducing the AILD T cell line "lSignificantly less than the same culture containing fresh B cells, P < 0.01. T Significantly less than the same culture without AILD T cell line (657 ng/ml), P < 0.01.
cell line was also studied (Table IX) . In this study, the antibody 33.2.1 was able to completely overcome the stimulatory effects of the AILD T cell supernate. Control monoclonal antibodies had no effect.
Discussion
In this study, we found that the T cells of two patients with AILD and a T cell line from one produce a factor or factors The ability of the AILD T cell supernates to induce B cell proliferation was assessed in two assay systems. The first measured B cell activating function in that B cell proliferation was induced without addition of anti-/i or other B cell mitogens.
The second assay was a standard co-stimulatory assay; highly purified B cells were cultured with the AILD or control T cell supernates in the presence of a suboptimal dose of anti-s,. In these assays, T cells were carefully removed from B cell populations, a depletion that was confirmed both by cell sorter analysis and failure to respond to T cell mitogens. However, because the B cell population may not have been depleted of partially activated B cells, it is possible that the proliferation induced by anti-s alone or by BCGF alone represented addition to a signal already received in vivo before cell separation. Moreover, we do not know in this study whether the two assays measuring B cell activation or co-stimulation are measuring the same or different factors, nor whether any of the activities involve multiple factors. We do know that the culture supernates do not contain measurable amounts of IL-1 or IL-2; therefore, there was not a mere excessive production of all cytokines. Further study will be required for a full analysis of the factor or factors produced by the AILD T cells.
Previous studies have demonstrated spontaneous Ig production by MNC from AILD patients (8) . Our findings are consistent with those reports in that AILD T cells plus AILD B cells led to proliferation and Ig production (7, 10, 11) . However, in a previous study, AILD T plus AILD B plus PWM did not lead to proliferation (7) or to Ig production (10); unfortunately, those studies did not examine AILD T plus AILD B without PWM as we have. As a result, they may have come to an incomplete conclusion based upon their finding of proliferation when AILD B cells were cultured with normal T cells plus PWM. This result led to the conclusion that the AILD B cells were hyperactive. Our studies of the effects of PWM clarify the issue. In the presence of PWM, the AILD T cells led to marked suppression of Ig production. This is consistent with the findings of the incomplete studies cited above (7, 10, 11 (36, 37) . Moreover, we have recently cloned the AILD T cell line and have been able to separate a clone which is able to mediate helper functions but not suppressor functions. Thus, we believe that the different functions observed with the AILD T cell line might well derive from the functional heterogeneity within the line. Although the line does not mirror the T cell population in vivo, we believe that the T cell line represents cells which are critical to the AILD disease process.
The PWM suppression study may shed some light on previous studies of patients with SLE. Such patients manifest B cell hyperactivity in vivo and yet often have very poor responses to stimulation with PWM in vitro (21) (22) (23) (24) (25) . It is possible that PWM induces suppression in those circumstances similar to the way that it induced suppression with the AILD cells.
Other studies of immune abnormalities in patients with AILD have implicated Epstein-Barr virus (38) , impaired suppressor T cell function (9) , and autonomous B cell hyperactivity (7) . Moreover, occasional patients with AILD have been found to manifest impaired Ig production (10 (2-4, 6, 40-42) . Thus, one group could be an extreme example of autoimmune lymphoproliferation and another group of AILD patients an early form of a lymphoid malignancy. However, it is not always easy to distinguish those two possibilities as many years of study of autoimmunelymphoproliferative mice indicate. Those mice often, but not invariably, carry retroviruses (43) . The recent discovery of human retrovirus diseases (44) (45) (46) (47) (48) (49) (50) certainly raises the possibility that retroviruses may play a role in AILD. Just as infectious mononucleosis and Burkitt's lymphoma differ in being benign and malignant lymphoproliferation resulting from EpsteinBarr infection, so AILD may represent benign or malignant lymphoproliferation resulting from infection with one or more viruses. Inasmuch as studies of patients with Epstein-Barr infections have been quite informative, further study of AILD will undoubtedly shed light on various aspects of immune dysregulation in humans.
Our finding of T cell driven B cell hyperactivity could conceivably be exploited therapeutically. Current therapy of AILD is marred by the desire to control the lymphoproliferation and yet not further predispose the patient to the infectious complications that claim the lives of the majority of AILD patients. It might be possible to interfere selectively with certain T cell functions while leaving others intact. Alternatively, a direct effect on the B cells might be attempted. In this regard, our in vitro inhibition of T cell driven B cell activation with an anti-Ia-like antibody suggests the possibility that one might be able to modulate early events in B cell activation so 338 as to reduce but not eliminate B cell functions. Such a titration could, conceivably, allow the patient to experience a clinical benefit without the requirement for toxic drugs. Clearly much future research is necessary before such ideas leave the realm of speculation.
